Portal de Periódicos da CAPES

Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH

2015; American Association for the Advancement of Science; Volume: 350; Issue: 6266 Linguagem: Inglês

10.1126/science.aaa5004

1095-9203

Jihye Yun, Edouard Mullarky, Changyuan Lu, Kaitlyn Bosch, Adam Kavalier, Keith Rivera, Jatin Roper, Iok In Christine Chio, Ευγενία Γιαννοπούλου, Carlo Rago, Ashlesha Muley, John M. Asara, Jihye Paik, Olivier Elemento, Zhengming Chen, Darryl Pappin, Lukas E. Dow, Nickolas Papadopoulos, Steven S. Gross, Lewis C. Cantley,

Vitamin K Research Studies

Getting all stressed out by vitamin C Few experimental cancer therapies have incited as much debate as vitamin C. Yet the mechanistic effect of vitamin C on cancer cells is still poorly understood. Yun et al. studied human colorectal cancer cells with KRAS or BRAF mutations and found that they “handle” vitamin C in a different way than other cells, ultimately to their detriment (see the Perspective by Reczek and Chandel). Because a certain receptor is up-regulated in the mutant cells, they take up the oxidized form of vitamin C (dehydroascorbate). This leads to oxidative stress, inactivation of a glycolytic enzyme required by the mutant cells for growth, and finally cell death. Whether the selective toxicity of vitamin C to these mutant cells can be exploited therapeutically remains unclear. Science , this issue p. 1391 ; see also p. 1317